Detalles de la búsqueda
1.
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.
Leuk Lymphoma
; 64(2): 473-477, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36517990
Resultados
1 -
1
de 1
1
Próxima >
>>